Abstract
The disclosure provides gene therapy vectors, such as adeno-associated virus (AAV), designed for treatment of an Interferon regulatory factor 2 binding protein like (IRF2BPL) disorder.
Full Text
What is claimed is:
The disclosure provides gene therapy vectors, such as adeno-associated virus (AAV), designed for treatment of an Interferon regulatory factor 2 binding protein like (IRF2BPL) disorder.
Timeline
Filed
03/23/2026Published
07/09/2026Granted
Not AvailableIPC Codes(2)
C12N 15/86:Viral vectors
C12N 15/113:Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides